Collaboration

#Collaboration #Drug discovery

This week in drug discovery (7-11 February) 

News round-up by DDW’s Megan Thomas for 7-11 February, 2022  This week has proved eventful in terms of progression in the drug discovery industry. DDW’s Megan Thomas flags five news stories which display this.  1. Additional dose of Covid-19 vaccine is safe, says US trial … Read More

#News #Trending News

#Clinical trials #Collaboration

New organisation promises smart clinical trials for better health 

Protas, a non-profit organisation which was launched on January 24, will design and deliver large, inclusive, randomised clinical trials, working in collaboration with industry partners, medical charities, patient groups, academic researchers, and frontline clinical teams. Sanofi is its first strategic partner.  Outlook  By combining randomised trial design with effective technology and a collaborative… Read More

#News

#Collaboration #Drug discovery #Oncology

Drug discovery collaboration to progress inhibitor project  

Domainex has supported the collaboration between Queen’s University Belfast (UK) and Ipsen to research, develop, manufacture and commercialise FLIP inhibitors – a programme that Domainex has supported since its inception.  Background  At the start of the project, Domainex conducted a LeadBuilder virtual screen that generated the initial hit matter. Read More

#News

#Collaboration #Funding #Investment

CellCentric secures investment to advance targeted cancer therapy 

CellCentric has received funding from BrightEdge to further progress the clinical development of its targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional investment from existing lead investor, Morningside Investments Limited.  What is inobrodib?  Inobrodib is a first-in-class small molecule inhibitor that impacts twin regulatory proteins p300… Read More

#News

#Biotechnology #Cell and gene therapy #Collaboration

Collaboration leads to new centre for cell therapy manufacturing 

Orgenesis, a global biotech company working with cell and gene therapies, and The Johns Hopkins University in the US, have collaborated to construct a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in the second quarter of… Read More

#News

#Collaboration #Comment #Drug discovery #Lab automation #SLAS2022

Comment: SLAS’ strength is collaboration 

The Winter issue of the Drug Discovery World Magazine is accompanied by an exclusive DDW & SLAS2022 supplement ahead of SLAS2022 in Boston, US on 5-9 February. As we all look forward to the expertise at the event, Jill Hronek, Director of Marketing and Communications at SLAS, comments that collaboration has always been key for the… Read More

#Editor's Choice #Exclusive Content #News

#Collaboration #Drug delivery #Funding #Research

12 new grants for infectious disease and antimicrobial resistance 

The Bloomsbury SET – a knowledge exchange programme led by the UK’s Royal Veterinary College (RVC) – has announced a Commercialisation Pilot of 12 new grants for projects which will develop tools to better fight infectious disease or antimicrobial resistance (AMR). Supported by more than £1 million of funding, these projects will bring together researchers and businesses… Read More

#News

#AI / data analytics / healthtech / informatics #Bioinformatics #Biopharmaceuticals #Biotechnology #Collaboration

Scitara joins collaboration to drive biopharmaceutical advancements  

Scitara has become a member of BioPhorum, a global community that enables collaboration throughout the biopharmaceutical industry with the goal of accelerating scientific advancements.  The Lab of the Future  Scitara joins BioPhorum Information Technology, which aims to accelerate digital maturity across the global biomanufacturing industry. One of the programmes within the portfolio,… Read More

#News

#Antibodies #Biotechnology #Collaboration #Neurodegenerative disorders #Neuroscience

Neurodegenerative collaboration seeks novel drug candidates 

Neurimmune has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical, which is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform, an antibody drug creation approach.  Background  In November 2017, Ono and Neurimmune signed… Read More

#News

#Acquisition #Collaboration #Oncology #T-Cells #Therapeutics

Takeover plan looks to develop T cell engager therapies 

Tokyo-based Takeda Pharmaceutical has optioned to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.   The acquisition   Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programmes. Adaptate’s γδ T cell engagers are… Read More

#News

#Collaboration #Drug candidates #Drug discovery

Drug discovery collaboration tackles metabolic diseases

Evotec has entered into a drug discovery collaboration with Eli Lilly and Company (Lilly) in the field of metabolic diseases with a focus on kidney diseases and diabetes.  The collaboration  The collaboration leverages Evotec’s metabolic disease experience, as well as its kidney disease patient database,… Read More

#News

Artificial Intelligence
#AI / data analytics / healthtech / informatics #Collaboration #Drug discovery

BenevolentAI announces collaboration with AstraZeneca 

BenevolentAI, a clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership.   The expansion  The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and… Read More

#News

#Collaboration #Research study

This week in drug discovery (10-14 January) 

News round-up by DDW’s Megan Thomas for 10-14 January, 2022  Studies, approvals and research are at the heart of drug discovery, which has been exemplified in this week’s drug discovery news. Megan Thomas has rounded up her top five stories of the week.   Vaccine-like mRNA injection can be… Read More

#News #Trending News

#Cancer immunotherapy #Collaboration #Drug design #Drug targets #Oncology

Collaboration will investigate next-generation cancer therapies 

PhoreMost, a UK-based biopharmaceutical company developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, have collaborated to study oncology targets currently considered undruggable.   The agreement  The POLARISqb Tachyon quantum computing platform will be used to scan billions of… Read More

#News

#AI #Collaboration #Drug development #Drug discovery

Exscientia and Sanofi to develop AI-driven medicines 

Sanofi and Exscientia have announced a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples.   Background  The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small… Read More

#News